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in pregnancy with sulfadoxine–pyrimethamine: 
a counter perspective
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Abstract 
Malaria continues to cause devastation during pregnancy. Unfortunately, there is still no clear strategy to effectively 
protect pregnant women and countless mothers living in malaria endemic countries are dying every year. The effec-
tive prevention of malaria during pregnancy will take much more than the so-called “Global Call for Action” for an 
intervention (IPTp-SP) that cannot succeed. A new and truly “global” strategy is urgently needed.
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Background
Despite recent progress, malaria continues to cause 
devastation during pregnancy. Not so long ago, asymp-
tomatic pregnant women infected with Plasmodium 
falciparum in Africa were left untreated. However it is 
now clear that even when silent, a low-density parasi-
taemia is deleterious to the mother and the fetus [1]. 
In areas of intense transmission, P. falciparum kills the 
mothers because they become severely anaemic, while 
in area of low transmission, they die of severe and cer-
ebral malaria. Plasmodium vivax is also responsible for 
maternal anaemia, poor fetal growth and the loss of the 
fetus in early pregnancy [2]. All this suffering affecting 
poor rural communities is readily preventable: malaria 
parasites already present in the maternal circulation must 
be promptly detected and eliminated and new infections 
totally prevented. Unfortunately, there is no clear strategy 
to achieve this objective and countless mothers are dying 
every year. A new and truly “Global” strategy is urgently 
needed.
In their opinion paper, Chico and colleagues [3] lament 
at the low up-take of intermittent preventive treat-
ment with sulfadoxine–pyrimethamine (SP) (IPTp-SP) 
in pregnant women at risk of malaria. They call upon all 
“key stakeholders” nationally and internationally to join 
their “Global Call to Action for the scale-up of IPTp”. A 
detailed list of actions is proposed that will, in their view, 
lead to achieve rapidly maximum coverage and public 
health impact. However, this rather desperate “plea” is 
unlikely to be heard, for several reasons:
1. The call is not “global” since it focuses only on cer-
tain areas of sub-Saharan Africa. In areas of low 
transmission, the malaria attributable maternal 
mortality can be higher than that in hyper-endemic 
Africa [4]. Chico et al. start their paper with the usual 
misleading statement, about preventing malaria in 
pregnancy, while in fact IPTp-SP (sometimes and 
more correctly referred to as Intermittent Presump-
tive treatment [5]) is about episodic treatments of P. 
falciparum infections in pregnant women living in 
rapidly shrinking areas of Africa where SP remains 
effective, de-facto ignoring the millions of women 
exposed to all malaria species elsewhere in Africa 
and in the rest of the world.
2. IPTp-SP is essentially taking advantage of the post-
treatment prophylactic effect of the slowly elimi-
nated pyrimethamine [5] so it amounts to intermit-
tent prophylaxis, leaving the women unprotected for 
significant period of time. Sulfadoxine–pyrimeth-
amine is an old anti-malarial used in the treat-
ment of uncomplicated P. falciparum infections. Its 
main advantages are that it can be used as a single 
dose and that its slow elimination provides a period 
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of protection against new infections for several 
weeks after treatment. It is not used at prophylactic 
doses because of the risk of serious toxicity. Resist-
ance to SP emerged in South East Asia in 1970 and 
has spread to large parts of Africa, where ACT has 
replaced it. Given its pharmacokinetic properties, 
SP in four treatment doses cannot truly “prevent” 
malaria in pregnant women for the duration of the 
gestation. It can only temporarily eliminate and sup-
press parasitaemia in areas where P. falciparum is 
still susceptible. But new infections will occur once 
the drug is eliminated. That’s far from the concept of 
prevention.
3. SP is a failed drug in large parts of Africa and the 
more recent studies show that the often quoted 
positive but indirect impacts (on birthweight and 
anaemia) are seriously compromised by resistance 
[1, 6]. It can also cause harm by increasing placen-
tal proliferation of resistant parasites [7], and by 
increasing gametocyte carriage. There is no direct 
evidence to support the claim by Chico et al. [3] that 
IPTp-SP reduces maternal mortality. It also unclear 
whether the dose administered to pregnant women 
is adequate. In any case, the call to action comes far 
too late for SP and a complete change of action is 
required [8].
4. The evidence for the beneficial effects of IPTp-SP 
is weak. The preferred (because easier to measure) 
endpoints in IPTp trials are maternal anaemia and 
birthweight. However, these are indirect markers of 
malaria infection and surely the absence of parasites 
in the maternal circulation (including the placenta) 
during gestation should be the primary objective 
and maternal mortality the primary endpoint. There 
is ample evidence that even asymptomatic low para-
sitaemia at any time during pregnancy has deleteri-
ous effects on the mother and the fetus. If one can 
really prevent malaria parasites to infect the mother 
during pregnancy, then all their deleterious impacts 
will be prevented as well. In poor, malaria affected 
communities in the rural world, women do not really 
care whether their baby is born 100 g heavier or not. 
They have no time for this. They are often more pre-
occupied with the daily struggle for survival. Call for 
action should be about interventions that increase 
their chance of survival. IPTp-SP at each routine 
ANC visit will not do this, because it cannot.
5. One puzzling question is that of double standards 
in WHO recommendations: for the treatment of 
malaria it recommends that new anti-malarial drugs 
should have >95% parasitological efficacy and that 
they should be replaced if the efficacy drops below 
90%. So why does WHO continue to recommend 
using drugs in pregnancy that have much lower rates 
of efficacy against a potential fatal infection?
The effective prevention of malaria during pregnancy 
will take much more than a “Global Call for Action” 
for a strategy (IPTp-SP) that cannot succeed. Mothers 
are dying even in areas of low and unstable transmis-
sion, and fetuses are being lost to malaria even when 
the mothers have no symptoms. So unless the protec-
tion against the malaria parasite is effective in the first 
place, the goal will remain elusive. A substantial reduc-
tion of maternal mortality and morbidity will probably 
result from a combination of interventions: the overall 
decline of malaria transmission in the entire popula-
tion, the protection of the mothers with LLINs and other 
vector control measures, and the intelligent use of safe 
anti-malarials that can kill any existing parasites in the 
circulation and prevent any new ones from infecting the 
women.
As experience has shown for the treatment of severe 
malaria [9], only strong and irrefutable evidence will 
change policy. What one should be calling for is a large 
international mortality trial comparing IPTp-SP with an 
effective drug regimen, for example monthly DHA–pipe-
raquine [10], including detailed pharmacokinetic assess-
ments to ensure correct dosing.
Authors’ contribution
FN and RM wrote the manuscript. Both authors read and approved the final 
manuscript.
Author details
1 Nuffield Department of Medicine, Centre for Tropical Medicine, University 
of Oxford, Oxford, UK. 2 Shoklo Malaria Research Unit, Mahidol-Oxford Tropical 
Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae 
Sot, Thailand. 
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 11 May 2015   Accepted: 4 June 2015
References
 1. Cottrell G, Moussiliou A, Luty AJ, Cot M, Fievet N, Massougbodji A et al 
(2015) Submicroscopic Plasmodium falciparum infections are associated 
with maternal anemia, premature births, and low birth weight. Clin Infect 
Dis 60:1481–1488
 2. McGready R, Lee S, Wiladphaingern J, Ashley E, Rijken M, Boel M et al 
(2012) Adverse effects of falciparum and vivax malaria and the safety of 
antimalarial treatment in early pregnancy: a population-based study. 
Lancet Infect Dis 12:388–396
 3. Chico RM, Dellicour S, Roman E, Mangiaterra V, Coleman J, Menendez C 
et al (2015) Global call to action: maximize the public health impact of 
intermittent preventive treatment of malaria in pregnancy in sub-Saha-
ran Africa. Malar J 14:207
Page 3 of 3Nosten and McGready.  Malar J  (2015) 14:248 
 4. Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, Syafruddin D 
et al (2012) Malaria in pregnancy in the Asia-Pacific region. Lancet Infect 
Dis 12:75–88
 5. White NJ (2005) Intermittent presumptive treatment for malaria. PLoS 
Med 2:e3
 6. McGready R, White NJ, Nosten F (2011) Parasitological efficacy of 
antimalarials in the treatment and prevention of falciparum malaria in 
pregnancy 1998 to 2009: a systematic review. BJOG 118:123–135
 7. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE 
(2011) Intermittent treatment to prevent pregnancy malaria does not 
confer benefit in an area of widespread drug resistance. Clin Infect Dis 
53:224–230
 8. Harrington W, McGready R, Muehlenbachs A, Fried M, Nosten F, Duffy 
P (2012) Intermittent preventive treatment in pregnancy with sulf-
adoxine–pyrimethamine: the times they are a-changin’. Clin Infect Dis 
55:1025–1026
 9. Treatment Guidelines for the Treatment of Malaria (2015). http://www.
who.int/malaria/publications/atoz/9789241549127/en/. Accessed 5 June 
2015
 10. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ et al 
(2012) A randomised, double-blind, placebo controlled trial of monthly 
versus second monthly dihydroartemisinin–piperaquine chemopreven-
tion in adults at high risk of malaria. Antimicrob Agents Chemother 
56:1571–1577
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
